Crossmark

Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Crossref DOI link: https://doi.org/10.1038/s41409-022-01702-w

Published Online: 2022-05-16

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alexander, Tobias https://orcid.org/0000-0003-1193-0097
Greco, Raffaella https://orcid.org/0000-0002-6117-5328
License Information

Text and Data Mining valid from 2022-05-16

Version of Record valid from 2022-05-16
More Information

Article History

Received: 26 February 2022

Revised: 26 April 2022

Accepted: 29 April 2022

First Online: 16 May 2022

Competing interests

: RG discloses speaking honoraria from Biotest, Pfizer, Medac, and Magenta. TA declares speaking honoraria from Amgen, Roche, Pfizer, travel grants from Neovii, and study support from Amgen, Janssen-Cilag, and Miltenyi Biotec.

: This review was led and supported by the EBMT-ADWP. The EBMT provided resources via the working party, data office, and registry. Other than EBMT support there is no funding body supporting these guidelines, commercial or otherwise.

Document is current

Any future updates will be listed below